MARKET

BTAI

BTAI

Bioxcel Therapeutics Inc
NASDAQ
1.540
-0.080
-4.94%
After Hours: 1.540 0 0.00% 17:04 02/12 EST
OPEN
1.620
PREV CLOSE
1.620
HIGH
1.638
LOW
1.525
VOLUME
234.76K
TURNOVER
--
52 WEEK HIGH
8.08
52 WEEK LOW
1.170
MARKET CAP
33.68M
P/E (TTM)
-0.1480
1D
5D
1M
3M
1Y
5Y
1D
BioXcel Highlights IGALMI At-Home Acute Agitation Opportunity
TipRanks · 10h ago
BioXcel Therapeutics Reports Strong Prescriber Interest, Patient Demand, And Positive Payer Feedback Supporting Broad Formulary Coverage For IGALMI In The Acute Treatment Of Agitation
Benzinga · 10h ago
BioXcel completes updated market opportunity assessment for Igalmi
TipRanks · 10h ago
BioXcel Therapeutics Unveils IGALMI At-Home Agitation Treatment Opportunity for Bipolar Disorder and Schizophrenia
Reuters · 10h ago
Weekly Report: what happened at BTAI last week (0202-0206)?
Weekly Report · 3d ago
BioXcel sets milestone bonuses amid pivotal IGALMI review
TipRanks · 6d ago
BioXcel Therapeutics führt neue Bonusvereinbarungen für Führungskräfte ein
Reuters · 6d ago
BioXcel Therapeutics Announces Milestone and Retention Bonus Plan for Senior Management
Reuters · 6d ago
More
About BTAI
BioXcel Therapeutics, Inc. is a biopharmaceutical company utilizing artificial intelligence to develop medicines in neuroscience. Its subsidiary, OnkosXcel Therapeutics LLC, is focused on the development of medicines in immuno-oncology. Its advanced neuroscience candidate, BXCL501, is an investigational, orally dissolving film formulation of dexmedetomidine in development for the treatment of agitation associated with psychiatric and neurological disorders. It is continuing to develop BXCL501 for the potential acute treatment of agitation associated with bipolar disorder or schizophrenia in the at-home setting and for the potential acute treatment of agitation (non-daily) associated with dementia due to probable Alzheimer’s disease in the at-home setting and in care facilities. Its advanced immuno-oncology candidate, BXCL701, is an investigational oral innate immune activator for the treatment of aggressive forms of prostate cancer, pancreatic cancer, and other solid and liquid tumors.

Webull offers BioXcel Therapeutics Inc stock information, including NASDAQ: BTAI real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, BTAI stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading BTAI stock methods without spending real money on the virtual paper trading platform.